HALIFAX, NOVA SCOTIA--(Marketwired - Nov. 24, 2015) - MedMira Inc. (MedMira) (TSX VENTURE:MIR) reported today on its financial results for the quarter and year ended July 31, 2015. The Company recorded a 60% increase in revenue and a 52% increase in gross profit at the fiscal year end compared to the prior year.
"The Company improved its financial performance in 2015 with positive gains in revenue and gross profit over the previous year," said Markus Meile, Chief Financial Officer, MedMira Inc. "Increasing sales in strategic high margin markets, strengthening of our brand position, and a focus on high value innovation using the patented MedMira Rapid Vertical Flow Technologyä platform were the primary drivers. The Company looks to carry this momentum forward in 2016."
Financial Highlights
About MedMira
MedMira is the developer and owner of Rapid Vertical Flow (RVF) Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad™ brands in global markets. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in Atlanta, Georgia, United States. For more information visit medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information: